1. Home
  2. PROK vs SDHI Comparison

PROK vs SDHI Comparison

Compare PROK & SDHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROK
  • SDHI
  • Stock Information
  • Founded
  • PROK 2015
  • SDHI 2024
  • Country
  • PROK United States
  • SDHI United States
  • Employees
  • PROK N/A
  • SDHI N/A
  • Industry
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • SDHI Blank Checks
  • Sector
  • PROK Health Care
  • SDHI Finance
  • Exchange
  • PROK Nasdaq
  • SDHI Nasdaq
  • Market Cap
  • PROK 384.2M
  • SDHI 352.4M
  • IPO Year
  • PROK N/A
  • SDHI 2025
  • Fundamental
  • Price
  • PROK $2.17
  • SDHI $10.16
  • Analyst Decision
  • PROK Buy
  • SDHI
  • Analyst Count
  • PROK 5
  • SDHI 0
  • Target Price
  • PROK $6.25
  • SDHI N/A
  • AVG Volume (30 Days)
  • PROK 1.7M
  • SDHI 123.0
  • Earning Date
  • PROK 08-12-2025
  • SDHI 01-01-0001
  • Dividend Yield
  • PROK N/A
  • SDHI N/A
  • EPS Growth
  • PROK N/A
  • SDHI N/A
  • EPS
  • PROK N/A
  • SDHI N/A
  • Revenue
  • PROK $527,000.00
  • SDHI N/A
  • Revenue This Year
  • PROK $265.05
  • SDHI N/A
  • Revenue Next Year
  • PROK N/A
  • SDHI N/A
  • P/E Ratio
  • PROK N/A
  • SDHI N/A
  • Revenue Growth
  • PROK N/A
  • SDHI N/A
  • 52 Week Low
  • PROK $0.46
  • SDHI $10.02
  • 52 Week High
  • PROK $7.13
  • SDHI $11.35
  • Technical
  • Relative Strength Index (RSI)
  • PROK 41.52
  • SDHI N/A
  • Support Level
  • PROK $2.23
  • SDHI N/A
  • Resistance Level
  • PROK $2.44
  • SDHI N/A
  • Average True Range (ATR)
  • PROK 0.15
  • SDHI 0.00
  • MACD
  • PROK -0.02
  • SDHI 0.00
  • Stochastic Oscillator
  • PROK 6.07
  • SDHI 0.00

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

About SDHI Siddhi Acquisition Corp Class A Common stock

Siddhi Acquisition Corp is a blank check company.

Share on Social Networks: